Over the last five years we have followed the trials and tribulations of CAR T cell therapies in ALL and aggressive lymphomas as Novartis, Kite, Juno, Cellectis, Unum and others have undertaken the road less travelled towards filing and approval.
The ASH DASH in action!
Now that we have seen the first two CAR T cell approvals in pediatric ALL (Novartis) and aggressive lymphomas (Kite), with tisagenlecleucel widely expected to be the next one in aggressive lymphomas following presentation of the 6-month JULIET data at the recent American Society of Hematology (ASH) meeting in Atlanta, a key question remains to be addressed:
Is there a threat on the horizon that might be potentially used prior to CAR T cell therapy in refractory lymphomas?
We say ‘yes, there is’ and thus it was interesting to see where this approach might go… including discussion with an expert.
To learn more and get a heads up on our latest insights, subscribers can log-in or you can click to gain access to BSB Premium Content.
SITC 2017 at the Gaylord Hotel, MD
It’s that time of year already and it has come around so fast in 2017… yes it’s the annual meeting for the Society for Immunotherapy of Cancer (aka SITC).
This year there are several eagerly anticipated presentations, one of which is Juno’s ill-fated ROCKET trial in adult ALL using their JCAR015 CAR T cell therapy.
While Novartis and Kite both successfully made it to market recently in pediatric ALL and aggressive lumphomas, respectively, Juno were left languishing in a poor third place after a series of lethal cerebral oedemas scuppered the program. In the meantime, Novartis are relentless chasing Kite with their JULIET trial in DLBCL and could well have the third CAR T cell therapy indication.
Finally, we heard for the first time today what the company learned from the recent analysis of the deaths, which they shared with the field this morning. BSB was on the spot to hear more about what the CMO, Dr Mark Gilbert had to say and we also have some thought leader sentiments on their perspective of the findings.
That’s not all though, as there was also new data on checkpoint blockade and other immunotherapies that are in early development as well as developments on the biomarker front.
To learn more insights on the latest conference coverage, subscribers can log-in or you can click to gain access to BSB Premium Content for our Day 1 highlights.
And we’re off on the infamous ASH DASH…
Atlanta Centennial Olympic Park
The annual data drop for the American Society of Hematology (ASH) meeting in Atlanta, Georgia is finally here.
Each year we write a series of in-depth previews ahead of the event exploring different aspects of hematologic malignancies in terms of what’s important, what to watch out for, and also key abstracts that may (or may not) have an impact.
This year we kick off the first of our series with a look at aggressive lymphomas and novel therapies in development including CAR T cell therapies, antibodies, ADCs and targeted therapies. There are some surprsies (of course) and also some potentially interesting relationships and consequences to consider.
To learn more insights on this intriguing topic, subscribers can log-in or you can click to gain access to BSB Premium Content.